EDITAS MEDICINE, INC. Revenue Breakdown
No Revenue Breakdown for EDIT on this site yet.
- 2025-12-31: Others Not split by product in the filing$40.52M100.00%; Total revenue $40.52M.
- 2024-12-31: Others Not split by product in the filing$32.31M100.00%; Total revenue $32.31M.
- 2023-12-31: Others Not split by product in the filing$78.12M100.00%; Total revenue $78.12M.
- 2022-12-31: Others Not split by product in the filing$19.71M100.00%; Total revenue $19.71M.
Source checked: the stored Revenue Breakdown page for EDIT.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $40.52M 100.00% | $40.52M |
| 2024-12-31 | Not split by product in the filing $32.31M 100.00% | $32.31M |
| 2023-12-31 | Not split by product in the filing $78.12M 100.00% | $78.12M |
| 2022-12-31 | Not split by product in the filing $19.71M 100.00% | $19.71M |
| 2021-12-31 | Not split by product in the filing $25.54M 100.00% | $25.54M |
| 2020-12-31 | Not split by product in the filing $90.73M 100.00% | $90.73M |
| 2019-12-31 | Not split by product in the filing $20.53M 100.00% | $20.53M |
| 2018-12-31 | Not split by product in the filing $31.94M 100.00% | $31.94M |
| 2017-12-31 | Not split by product in the filing $13.73M 100.00% | $13.73M |
| 2016-12-31 | Not split by product in the filing $6.05M 100.00% | $6.05M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $11.89M 100.00% | $11.89M |
| 2026-03-31 | Not split by product $2.83M 100.00% | $2.83M |
| 2025-12-31 | Not split by product $24.74M 100.00% | $24.74M |
| 2025-09-30 | Not split by product $7.54M 100.00% | $7.54M |
| 2025-06-30 | Not split by product $3.58M 100.00% | $3.58M |
| 2025-03-31 | Not split by product $4.66M 100.00% | $4.66M |
| 2024-12-31 | Not split by product $30.60M 100.00% | $30.60M |
| 2024-09-30 | Not split by product $61.00K 100.00% | $61.00K |
| 2024-06-30 | Not split by product $513.00K 100.00% | $513.00K |
| 2024-03-31 | Not split by product $1.14M 100.00% | $1.14M |
| 2023-12-31 | Not split by product $60.05M 100.00% | $60.05M |
| 2023-09-30 | Not split by product $5.34M 100.00% | $5.34M |
| 2023-06-30 | Not split by product $2.89M 100.00% | $2.89M |
| 2023-03-31 | Not split by product $9.85M 100.00% | $9.85M |
| 2022-12-31 | Not split by product $6.54M 100.00% | $6.54M |
| 2022-09-30 | Not split by product $42.00K 100.00% | $42.00K |
| 2022-06-30 | Not split by product $6.36M 100.00% | $6.36M |
| 2022-03-31 | Not split by product $6.77M 100.00% | $6.77M |
| 2021-12-31 | Not split by product $12.47M 100.00% | $12.47M |
| 2021-09-30 | Not split by product $6.20M 100.00% | $6.20M |
| 2021-06-30 | Not split by product $379.00K 100.00% | $379.00K |
| 2021-03-31 | Not split by product $6.50M 100.00% | $6.50M |
| 2020-12-31 | Not split by product $11.42M 100.00% | $11.42M |
| 2020-09-30 | Not split by product $62.84M 100.00% | $62.84M |
| 2020-06-30 | Not split by product $10.75M 100.00% | $10.75M |
| 2020-03-31 | Not split by product $5.72M 100.00% | $5.72M |
| 2019-12-31 | Not split by product $12.28M 100.00% | $12.28M |
| 2019-09-30 | Not split by product $3.85M 100.00% | $3.85M |
| 2019-06-30 | Not split by product $2.33M 100.00% | $2.33M |
| 2019-03-31 | Not split by product $2.07M 100.00% | $2.07M |
| 2018-12-31 | Not split by product $6.12M 100.00% | $6.12M |
| 2018-09-30 | Not split by product $14.52M 100.00% | $14.52M |
| 2018-06-30 | Not split by product $7.37M 100.00% | $7.37M |
| 2018-03-31 | Not split by product $3.93M 100.00% | $3.93M |
| 2017-12-31 | Not split by product $3.67M 100.00% | $3.67M |
| 2017-09-30 | Not split by product $6.28M 100.00% | $6.28M |
| 2017-06-30 | Not split by product $3.10M 100.00% | $3.10M |
| 2017-03-31 | Not split by product $682.00K 100.00% | $682.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |